Gamma-aminobutyric acid type A receptor alpha-2 subunit (GABRA2)

The Gamma-aminobutyric acid type A receptor alpha-2 subunit (GABRA2) is a critical component of the heteropentameric GABA-A receptor, the primary inhibitory neurotransmitter receptor in the mammalian central nervous system. These receptors function as ligand-gated chloride channels; upon binding of GABA, the channel opens, allowing chloride ions to enter the neuron, which hyperpolarizes the cell and inhibits action potential firing (Source: UniProt P47869). The alpha-2 subunit is specifically localized in brain regions associated with emotional processing, such as the amygdala and hippocampus, and is a key mediator of the anxiolytic and muscle-relaxant effects of benzodiazepines (Source: PubMed 10805772). Dysfunction or genetic variations in the GABRA2 gene have been strongly linked to the pathogenesis of anxiety disorders, epilepsy, and substance use disorders, particularly alcohol dependence (Source: PubMed 15138899). In drug development, the alpha-2 subunit is a high-priority target for 'subtype-selective' modulators. The goal is to develop compounds that provide the therapeutic benefits of traditional benzodiazepines—such as reduced anxiety and anticonvulsant activity—without the dose-limiting side effects of sedation and ataxia, which are primarily mediated by the alpha-1 subunit (Source: PubMed 21654917). Current research focuses on positive allosteric modulators (PAMs) that selectively target alpha-2/3 containing receptors to treat chronic pain and psychiatric conditions.

Other names

GABA(A) receptor subunit alpha-2GABA_A receptor alpha-2 subunitGABRA2Gamma-aminobutyric acid receptor subunit alpha-2

Positive allosteric modulation of the GABA-A receptor complex, increasing the frequency of chloride channel opening in response to GABA binding, which leads to post-synaptic hyperpolarization and reduced neuronal firing.